Cloning and expression in Escherichia coli of the gene for human tumour necrosis factor

Nature ◽  
1985 ◽  
Vol 313 (6005) ◽  
pp. 803-806 ◽  
Author(s):  
Takashi Shirai ◽  
Hiroshi Yamaguchi ◽  
Hirataka Ito ◽  
Chas. W. Todd ◽  
R. Bruce Wallace
Keyword(s):  
Escherichia Coli ◽  
Tumour Necrosis Factor ◽  
Tumour Necrosis ◽  
Cloning And Expression ◽  
Human Tumour ◽  
Expression In Escherichia Coli ◽  
Human Tumour Necrosis Factor ◽  
Necrosis Factor

Efficient production of human tumour necrosis factor in Escherichia coli

1985 ◽  
Vol 3 (3) ◽  
pp. 141-153 ◽  
Author(s):  
Masaaki Yamada ◽  
Yasuji Furutani ◽  
Mitsue Notake ◽  
Jun-ichi Yamagishi ◽  
Michiko Yamayoshi ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Tumour Necrosis Factor ◽  
Tumour Necrosis ◽  
Efficient Production ◽  
Human Tumour ◽  
Human Tumour Necrosis Factor ◽  
Necrosis Factor

scholarly journals Optimizing host cell physiology and stress avoidance for the production of recombinant human tumour necrosis factor α in Escherichia coli

Microbiology ◽  
2018 ◽  
Vol 164 (4) ◽  
pp. 440-452 ◽  
Author(s):  
Tania Selas Castiñeiras ◽  
Steven G. Williams ◽  
Antony Hitchcock ◽  
Jeffrey A. Cole ◽  
Daniel C. Smith ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Host Cell ◽  
Tumour Necrosis Factor ◽  
Tumour Necrosis ◽  
Cell Physiology ◽  
Tumour Necrosis Factor Α ◽  
Human Tumour ◽  
Human Tumour Necrosis Factor ◽  
Factor Α ◽  
Necrosis Factor

Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin

Nature ◽  
1984 ◽  
Vol 312 (5996) ◽  
pp. 724-729 ◽  
Author(s):  
Diane Pennica ◽  
Glenn E. Nedwin ◽  
Joel S. Hayflick ◽  
Peter H. Seeburg ◽  
Rik Derynck ◽  
...  
Keyword(s):  
Tumour Necrosis Factor ◽  
Tumour Necrosis ◽  
Human Tumour ◽  
Precursor Structure ◽  
Human Tumour Necrosis Factor ◽  
Necrosis Factor

Expression and rescuing of a cloned human tumour necrosis factor gene using an EBV-based shuttle cosmid vector.

1987 ◽  
Vol 6 (2) ◽  
pp. 355-361 ◽  
Author(s):  
D. Kioussis ◽  
F. Wilson ◽  
C. Daniels ◽  
C. Leveton ◽  
J. Taverne ◽  
...  
Keyword(s):  
Tumour Necrosis Factor ◽  
Tumour Necrosis ◽  
Human Tumour ◽  
Factor Gene ◽  
Human Tumour Necrosis Factor ◽  
Cosmid Vector ◽  
Necrosis Factor

Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis.

1991 ◽  
Vol 10 (13) ◽  
pp. 4025-4031 ◽  
Author(s):  
J. Keffer ◽  
L. Probert ◽  
H. Cazlaris ◽  
S. Georgopoulos ◽  
E. Kaslaris ◽  
...  
Keyword(s):  
Transgenic Mice ◽  
Tumour Necrosis Factor ◽  
Tumour Necrosis ◽  
Genetic Model ◽  
Human Tumour ◽  
Human Tumour Necrosis Factor ◽  
Necrosis Factor

Model for Whole Body Production of Tumour Necrosis Factor-α in Experimental Endotoxaemia in Healthy Subjects

1994 ◽  
Vol 87 (4) ◽  
pp. 459-465 ◽  
Author(s):  
R. Koopmans ◽  
F. J. Hoek ◽  
S. J. H. van Deventer ◽  
T. van der Poll
Keyword(s):  
Tumour Necrosis Factor ◽  
Tumour Necrosis ◽  
Whole Body ◽  
Serum Concentrations ◽  
Tumour Necrosis Factor Α ◽  
Human Tumour ◽  
Human Tumour Necrosis Factor ◽  
Body Production ◽  
Factor Α ◽  
Necrosis Factor

1. Tumour necrosis factor-α is considered an important mediator in the pathophysiology of several diseases. Although much information is available about the serum concentrations of this cytokine in these illnesses, little is known about the production of tumour necrosis factor-α in disease in vivo. 2. In the present study we aimed to estimate the extent and the kinetics of whole body tumour necrosis factor-α synthesis in experimental endotoxaemia in six healthy humans. For this purpose we first examined the pharmacokinetic behaviour of an intravenously injected bolus of recombinant human tumour necrosis factor-α (50 μg/m2) in another group of six normal subjects. We then calculated the total amount of tumour necrosis factor-α produced after intravenous injection of endotoxin (2 ng/kg) as the product of the systemic clearance of recombinant human tumour necrosis factor-α (9.5 ± 5.0 ml min−1 kg−1) and the area under the tumour necrosis factor-α concentration-time curves in the endotoxaemic subjects. 3. Recombinant human tumour necrosis factor-α showed evident two-compartment kinetics with an initial rapid disappearance (t1/2 5.1 ± 2.2 min) and a terminal slower elimination (t1/2 49 ± 5 min). Tumour necrosis factor-α synthesis after endotoxin varied markedly between individuals, ranging from 11.8 to 114.1 μg (52.7 ± 34.7 μg). The changes in time of the serum concentrations of tumour necrosis factor-α after administration of endotoxin could be accurately described with an adapted two-compartment open model that incorporated both rapid tumour necrosis factor-α production (74% of the total amount) and slow tumour necrosis factor-α production (26%). 4. Our results suggest that, in endotoxaemia, circulating tumour necrosis factor-α originates from two different sources, one in rapid and one in slow equilibrium with the circulation. We propose that the pharmacokinetic characteristics of intravenous recombinant human tumour necrosis factor-α may be used to estimate the production of rumour necrosis factor-α in clinical disease.

Sign in / Sign up

Export Citation Format

Share Document